Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-MAFF (75-164) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MAFF |
Gene ID: |
23764 |
Uniprot ID: |
MAFF_HUMAN |
Immunogen Region: |
75-164 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 75-164 of human MAFF (NP_036455.1). |
Immunogen Sequence: |
QKEELQKQKSELEREVDKLA RENAAMRLELDALRGKCEAL QGFARSVAAARGPATLVAPA SVITIVKSTPGSGSGPAHGP DPAHGPASCS |
Tissue Specificity | Expressed in the term myometrium and kidney. |
Function | Since they lack a putative transactivation domain, the small Mafs behave as transcriptional repressors when they dimerize among themselves. However, they seem to serve as transcriptional activators by dimerizing with other (usually larger) basic-zipper proteins, such as NFE2L1/NRF1, and recruiting them to specific DNA-binding sites. Interacts with the upstream promoter region of the oxytocin receptor gene. May be a transcriptional enhancer in the up-regulation of the oxytocin receptor gene at parturition. |
Protein Name | Transcription Factor MaffU-MafV-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog F |
Database Links | Reactome: R-HSA-983231 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Transcription Factor Maff antibodyAnti-U-Maf antibodyAnti-V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog F antibodyAnti-MAFF antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance